Dual antiplatelet therapy duration and stent type in patients with high bleeding risk: A systematic review and network meta-analysis
Study context
- Population
- Patients with high bleeding risk (HBR) undergoing PCI
- Participants
- 19,418 patients13 randomized controlled trials (RCTs)
- Comparison
- Short dual antiplatelet therapy (DAPT) vs standard DAPT, by stent type
- Outcome
- MACE (CV death, MI and stroke); primary safety outcome major bleeding
Methodological detailsrandom effects model, PubMed and EMBASE searched until October 2023
- Random effects model
- PubMed and EMBASE searched until October 2023
Pooled result
As reported in the abstract
MACE
- Short DAPT with bare-metal stent (BMS) associated with higher risk of MACE and myocardial infarction (MI) vs standard DAPT with DP-DES
Further pooled results
| Outcome | HR (95% CI) | |
|---|---|---|
| Stent thrombosisStandard DAPT with BP-DESvs Short DAPT with DP-DESBP-DES associated with higher ST risk than DP-DES | 2.65 (1.03–6.79) | |
| 0.10.31310Hazard ratio (log scale) |
Safety
| Outcome | HR (95% CI) | |
|---|---|---|
| Major bleedingShort DAPT with DP-DESvs Standard DAPT with DP-DES | 0.48 (0.28–0.82) | |
| 0.20.5125Hazard ratio (log scale) |
Major bleeding
- Short DAPT strategies associated with lower risk than standard DAPT strategies
Original publication
Dual antiplatelet therapy duration and stent type in patients with high bleeding risk: A systematic review and network meta-analysis. Am Heart J. Published 5 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →